A potential time bomb in which the deadlier form now has the power to explode globally
Uma variante mais letal do Mpox emergiu no coração da África, carregando uma taxa de mortalidade dez vezes superior à cepa que varreu o mundo em 2022. A OMS convoca agora um comitê de emergência para avaliar se o surto — já responsável por mais de 500 mortes na República Democrática do Congo e presente em quatro países vizinhos — merece o mais alto nível de alerta sanitário internacional. O que está em jogo não é apenas uma doença, mas a pergunta recorrente da humanidade: até onde um vírus pode chegar antes que o mundo reaja a tempo?
- A variante Clade 1b do Mpox mata cerca de 10% dos infectados — uma letalidade dez vezes maior do que a cepa de 2022, que já havia alarmado o planeta inteiro.
- Com mais de 14.000 casos e 511 mortes apenas no Congo em 2024, o vírus cruzou fronteiras e chegou a Burundi, Quênia, Ruanda e Uganda — países que nunca haviam registrado a doença.
- A descoberta de que a variante mais letal também se transmite sexualmente acende um sinal vermelho: o mesmo vetor que tornou o HIV incontrolável pode agora impulsionar este surto para além do continente africano.
- A OMS convocou um comitê de emergência e abriu processo acelerado para aprovação de vacinas, enquanto o CDC Africano se prepara para declarar emergência continental — mas o acesso real às vacinas em países de baixa renda permanece a batalha mais difícil.
Na quarta-feira, o diretor-geral da Organização Mundial da Saúde anunciou a convocação de um comitê de emergência para avaliar se o avanço do Mpox na África configura uma emergência de saúde pública de importância internacional — o mais alto nível de alerta da organização. O que motivou essa decisão não foi apenas o aumento de casos, mas uma mudança fundamental no próprio vírus.
A República Democrática do Congo enfrenta um surto sem precedentes recentes: mais de 14.000 infectados e 511 mortos em 2024. Para contextualizar, o surto global de 2022 — que atingiu todos os continentes habitados e infectou 85.000 pessoas — resultou em pouco mais de 120 mortes. A cepa atual, chamada Clade 1b, tem taxa de mortalidade de aproximadamente 10%, dez vezes superior à variante que dominou 2022.
O vírus já ultrapassou fronteiras. Em apenas um mês, casos confirmados surgiram em quatro países vizinhos que nunca haviam registrado Mpox: Burundi, Quênia, Ruanda e Uganda. No continente, os diagnósticos saltaram 160% em relação a 2023, e pelo menos 16 dos 55 países africanos já estão afetados. O diretor do CDC Africano sinalizou que uma declaração de emergência continental deve ocorrer em dias.
O que torna o cenário ainda mais grave é a transmissão sexual. Durante o surto de 2022, o Mpox encontrou redes de contágio sexual que o projetaram globalmente. Agora, evidências indicam que a variante mais letal também adotou esse caminho — o mesmo que tornou o HIV tão difícil de conter, segundo epidemiologistas da Coalizão para Inovação em Preparação para Epidemias.
A OMS já convidou fabricantes de vacinas a submeter seus produtos para aprovação emergencial, um processo acelerado que pode ampliar o acesso, especialmente em países de baixa renda. O comitê de emergência se reunirá em breve. O que decidir moldará a resposta do mundo a um vírus que, em 2024, não é mais o mesmo de dois anos atrás.
On Wednesday, the director-general of the World Health Organization announced that an emergency committee would convene as soon as possible to determine whether the surge of Mpox cases across Africa constitutes a public health emergency of international concern—the organization's highest alert level. What has triggered this urgency is not simply a rise in cases, but a fundamental shift in the virus itself.
The Democratic Republic of Congo is experiencing an outbreak unlike anything seen in recent years. More than 14,000 people have been infected this year, and 511 have died. To understand the scale: the global Mpox outbreak of 2022, which reached every inhabited continent and infected 85,000 people, resulted in just over 120 deaths. The virus circulating now is different. It is a variant of Clade 1, the deadlier of the two known strains, and specifically a new branch called Clade 1b. This version carries a mortality rate of approximately 10 percent—ten times higher than the Clade 2 strain that drove the 2022 pandemic, which killed at roughly 1 percent of those infected.
What makes this moment particularly alarming is that the virus has already crossed borders. In the past month alone, confirmed cases and suspected infections have appeared in four neighboring countries that had never recorded Mpox: Burundi, Kenya, Rwanda, and Uganda. The African continent as a whole has seen diagnoses jump 160 percent compared to 2023, which itself had 60 percent more cases than 2022. At least 16 of Africa's 55 countries are now affected. The director of the African CDC said this week that his organization would likely declare a continental public health emergency within days, a designation that would unlock funding and accelerate access to vaccines and other tools.
The virus's ability to spread through sexual contact compounds the danger. During the 2022 outbreak, Mpox found its way into networks of sexual transmission, a shift that allowed it to propagate globally in ways the virus had never done before. Evidence now suggests that Clade 1, the more lethal variant, has also adapted to this mode of transmission. An epidemiologist from the Coalition for Epidemic Preparedness Innovation described the situation bluntly: the deadlier form of the disease has discovered the same transmission pathway that made HIV so difficult to contain. What was once a rare disease confined largely to Central Africa has found a highway.
Mpox itself is a viral illness from the same family as smallpox, which was eradicated in 1980. Initial symptoms include fever, muscle pain, fatigue, and swollen lymph nodes. The hallmark of the disease is a skin rash—blisters that typically begin on the face and spread across the body, particularly the hands and feet. When transmission occurs sexually, the lesions appear on the genitals. Symptoms emerge between six and thirteen days after exposure, though they can take up to three weeks to appear. In milder cases, the illness resolves on its own within two to three weeks.
The question now is whether this outbreak warrants the same emergency designation that was applied to Mpox in 2022 and to COVID-19. The WHO director-general has called the emergency committee to make that assessment. If declared, it would signal to the world that the threat has reached a critical threshold and would facilitate the rapid deployment of countermeasures. On Friday, the WHO issued a formal invitation to vaccine manufacturers to submit their Mpox vaccines for emergency use listing—a streamlined approval process designed to accelerate availability of medical products in public health crises. The organization is asking manufacturers to provide data demonstrating safety, efficacy, and quality assurance. Approval could dramatically speed vaccine access, particularly in low-income countries, and enable organizations like Gavi and UNICEF to procure doses for distribution.
The timing is urgent. The virus has accumulated mutations over the years, and the current version spreading across Africa in 2024 is not the one the world faced two years ago. It is more lethal, it has found new pathways of transmission, and it has already begun moving beyond the borders of the countries where it has long been endemic. The committee will meet soon. What they decide will shape the global response.
Notable Quotes
The virus accumulated mutations and we are at a moment to observe what impact they will have on this version circulating in 2024. What we see is that it is spreading in Africa and has a higher mortality rate than the version from two years ago.— Celso Granato, infectologist at Clínica Felippe Mattoso
The concerning part now is that this other clade, which has a mortality rate that could be up to 10 times greater, has also found its way to sexual transmission. We are looking at a potential time bomb in which the more dangerous form of the disease now has the potential to explode and spread globally.— Richard Hatchett, executive director of the Coalition for Epidemic Preparedness Innovation
The Hearth Conversation Another angle on the story
Why does it matter that this is a different strain than 2022? Isn't Mpox still Mpox?
The difference is mortality. The 2022 strain killed about 1 in 100 people who got it. This new one kills about 1 in 10. That's not a small distinction—it's the difference between a manageable outbreak and something far more dangerous.
But it's still mostly in Africa, right? Why should people elsewhere be concerned?
Because it's already in four countries that didn't have it before, and it's spreading through sexual contact. That's the same mechanism that made 2022 go global. Once a virus finds that pathway, geography becomes less of a barrier.
What does an emergency declaration actually do?
It unlocks resources and accelerates decisions. Vaccines can be approved faster. Funding flows more easily. Countries coordinate instead of acting alone. It's a signal that this is no longer a regional problem.
Are there vaccines ready?
There are vaccines developed for traditional smallpox that protect against Mpox. But the WHO is now asking manufacturers to submit them for emergency approval, which suggests the existing supply isn't sufficient for what's coming. That process takes time, even when expedited.
What's the worst-case scenario here?
A virus that's ten times deadlier than the 2022 strain, spreading through the same networks that made that outbreak global, but with much higher mortality. That's why the epidemiologist called it a potential time bomb.
Can people protect themselves?
Yes—avoiding close physical contact with infected people, including sexual contact, prevents transmission. But in places where the virus is already circulating in communities, that becomes harder to do without knowing who's infected.